CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 37 enrolled
Drug / intervention
Capsaicindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02766517
NCT02766517Early Ph 1Completed
CompareCT.gov

LY2951742 Biomarker Study in Patients With Migraine

Eli Lilly and Company·interventional·Posted May 9, 2016·Updated Apr 9, 2019

In Brief

A Early Phase 1 clinical trial evaluating Capsaicin for Migraine Disorders. Completed, enrolled 37 participants across 14 sites.

Detailed Summary

This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo. This study NCT02766517 will evaluate how certain biomarkers may be related to the participant's response in study NCT02163993. The study will last about five days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 9, 2016
Enrollment StartSep 28, 2016
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.1 years ago

Interventions

Capsaicindrug

Administered topically